Analytics Argenx’s Vyvgart Offers a Substantial Advance Over Other Treatments for Generalized Myasthenia… AIT News Desk Feb 15, 2022 Physician-reported treatment patterns suggest that Vyvgart prescriber base and share could soon be competitive with those of Alexion's (now…